We are proud to share that our President and CEO Dr. J. Jean Cui was recognized as one of the 11 Asian American executives shaping the future of biopharma by the Timmerman Report. This accolade further underscores Jean’s outstanding leadership, vision, and unwavering dedication to advancing medical innovation for the benefit of patients. View the full list here: https://bit.ly/3VuEK8r
BlossomHill Therapeutics, Inc.
Biotechnology Research
San Diego, CA 2,578 followers
Addressing urgent unmet medical needs through deeper Science, true originality, and rich experience...
About us
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A. BlossomHill Therapeutics, Inc. is headquartered in San Diego, California.
- Website
-
https://bhtherapeutics.com/
External link for BlossomHill Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Diego, CA
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
3525 John Hopkins Court
Suite 100
San Diego, CA 92121, US
Employees at BlossomHill Therapeutics, Inc.
Updates
-
We are thrilled to see our CEO, Dr. J. Jean Cui, featured in The Medicine Maker 2024 Power List! Her leadership and groundbreaking research have brought several cutting-edge medicines to patients in need. Join us in congratulating Dr. Cui on this prestigious recognition that underscores her commitment to developing medicines that make a difference in patients’ lives. More here: https://bit.ly/3Jm09K4
-
-
We’re looking forward to presenting at #AACR24! Don’t miss our poster presentations featuring preclinical data from our CLK inhibitor program. See more details below and view our abstracts here: https://bit.ly/3xkGmYM and https://bit.ly/49gHCJI American Association for Cancer Research
-
#ICYMI Matthew Herper of STAT sat down with our CEO, Dr. J. Jean Cui, to learn more about her story and mission to develop effective therapeutics that tackle drug resistance. Discover how Dr. Cui and BlossomHill are applying human intelligence and creativity to drug design with the goal of extending survival and improving quality of life for #cancer patients. Read the full article here: https://bit.ly/49NRCLA #precisionmedicine
-
Our CEO, Dr. J. Jean Cui, connected with BiotechTV’s Brad Loncar following our completion of a $100 million financing to gain insight into Dr. Cui’s perspective on #precisionmedicines and how we are working to solve unmet medical needs by re-envisioning #cancer drug development. Watch the full video here: https://bit.ly/3Isffxy
𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: BlossomHill Therapeutics, Inc. raises a $100M series B to work on precision medicine small molecules. Scientific founder, president & CEO J. Jean Cui describes the company's approach. Full video: https://lnkd.in/gfYWVuUT BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
We’re proud to announce the completion of a $100 million financing round to support us in making a leap forward and advancing our pipeline for the treatment of #cancer and #autoimmune diseases. Learn more about the news and our commitment to redefining #precisionmedicine: https://lnkd.in/euNFdMfy #Financing #Biotechnology
-
#ICYMI: Our President and CEO, Dr. J. Jean Cui, was recently elected to the National Academy of Engineering (NAE) for her innovation of new medicines to fight cancers and address urgent medical needs. Election to the NAE is among the highest professional distinctions accorded to an engineer and recognizes outstanding contributions to #engineering research and practice. Congratulations, Dr. Cui! More here: https://bit.ly/3wjDo6A #NAE2024
BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering
https://bhtherapeutics.com
-
Co-Founder, CEO and Chairman (10.2013-10.2018), Turning Point Therapeutics, Inc.; Co-Founder, Executive Chairman, BlossomHill Therapeutics, Inc.
Wow, official AUGTYRO™ information website is up 👍 👍 👍 FYI- Dr. J. Jean Cui.
AUGTYRO™ (repotrectinib) for ROS1 mNSCLC | HCP Website
augtyrohcp.com
-
Post by Dr. J. Jean Cui https://lnkd.in/gxWmhqfu
Co-Founder, President/CEO, BlossomHill Therapeutics, Inc.; Co-Founder, CSO, Turning Point Therapeutics, Inc. (10.2013-1.2020); Lead inventor of 3 FDA-approved oncology drugs; Academician, National Academy of Engineering.
Even though expected, but I still feel very emotional when heard the news of Repotrectinib approval by FDA. It is great news that ROS1 positive NSCLC patients have a new option for their treatment. I am grateful for all the support I received. Special thanks go to Dr. Sai-Hong Ignatius Ou who helped develop clinical trial plan from the very beginning for TPX-0005 (i.e. Repotrectinib). I am grateful to the clinicians, patients and their families, Turning Point team members, and investors. I am still on my journey to create more novel drugs that can help patients and save lives. Thank you. https://lnkd.in/g6BAK_td
FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1 NSCLC
onclive.com
-
Congratulations to Dr. J. Jean Cui, our President and CEO at BlossomHill!!
Co-Founder, CEO and Chairman (10.2013-10.2018), Turning Point Therapeutics, Inc.; Co-Founder, Executive Chairman, BlossomHill Therapeutics, Inc.
Big congratulations to Dr. J. Jean Cui who designed Repotrectinib molecule while at Turning Point Therapeutics, a biotech company she and I co-founded in 2013. This is the 3rd FDA approved oncology drug designed by Dr. Cui. Previous two are Crizotinib and Lorlatinib when she worked at Pfizer. Congratulations to Bristol-Myer for receiving this timely approval! Hugh thanks to all the people who have contributed to the development and approval of this novel medicine: Turning Point/BMS team members, clinicians, patients and their families, Turning Point investors, and government regulators/FDA. https://lnkd.in/gZnvUxrv
FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1 NSCLC
onclive.com